Thompson Siegel & Walmsley LLC Has $7.44 Million Stock Holdings in Elevance Health, Inc. $ELV

Thompson Siegel & Walmsley LLC boosted its stake in Elevance Health, Inc. (NYSE:ELV) by 7.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,230 shares of the company’s stock after purchasing an additional 1,475 shares during the period. Thompson Siegel & Walmsley LLC’s holdings in Elevance Health were worth $7,442,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Florida Financial Advisors LLC acquired a new stake in shares of Elevance Health during the fourth quarter valued at about $210,000. Waterloo Capital L.P. grew its holdings in Elevance Health by 17.3% during the 4th quarter. Waterloo Capital L.P. now owns 922 shares of the company’s stock worth $323,000 after acquiring an additional 136 shares during the last quarter. Nomura Asset Management Co. Ltd. increased its position in Elevance Health by 2.3% in the 4th quarter. Nomura Asset Management Co. Ltd. now owns 85,171 shares of the company’s stock valued at $29,857,000 after acquiring an additional 1,898 shares during the period. Mitchell Capital Management Co. acquired a new position in Elevance Health in the 4th quarter valued at approximately $4,528,000. Finally, PARUS FINANCE UK Ltd raised its stake in shares of Elevance Health by 1.4% during the fourth quarter. PARUS FINANCE UK Ltd now owns 11,239 shares of the company’s stock valued at $3,940,000 after acquiring an additional 150 shares during the last quarter. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on ELV shares. Guggenheim boosted their price objective on shares of Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Mizuho raised their price objective on Elevance Health from $385.00 to $435.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 20th. Bank of America upgraded Elevance Health from a “neutral” rating to a “buy” rating and upped their target price for the company from $405.00 to $435.00 in a report on Wednesday, April 29th. Barclays increased their target price on shares of Elevance Health from $408.00 to $480.00 and gave the company an “overweight” rating in a research report on Tuesday, May 26th. Finally, Weiss Ratings raised shares of Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, May 18th. Fourteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $407.05.

Elevance Health Price Performance

ELV opened at $402.69 on Tuesday. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $408.00. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The company has a market capitalization of $87.45 billion, a price-to-earnings ratio of 17.13, a P/E/G ratio of 2.22 and a beta of 0.66. The firm’s fifty day moving average price is $345.97 and its two-hundred day moving average price is $339.77.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The business had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The firm’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, analysts anticipate that Elevance Health, Inc. will post 26.94 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be paid a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s payout ratio is presently 29.26%.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.